ClinicalTrials.gg
Status unknownNCT04513340Updated Sep 10, 2020

WD-1603 PK Study Under Fasting and Fed Conditions in Healthy Subjects

A Phase 1 interventional study of WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS in Parkinson Disease, sponsored by Hong Kong WD Pharmaceutical Co., Limited. Status unknown at 1 site in India. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-10.

Sponsored by Hong Kong WD Pharmaceutical Co., Limited · Phase 1, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Sep 2020), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies testing levodopa in Parkinson Disease — 3 open to participants now, 3 under way, none of them phase 3. Levodopa · Parkinson Disease.

Planned enrollment
48th of 50
8 · median 56
Started
2020
the only one that year
Phase 1
8 of 51
none open now
Registered
46th of 51
by date

Among the 51 studies testing levodopa in Parkinson Disease, this one is the 48th largest by planned enrollment of the 50 interventional ones that give a count, is the only one that started in 2020, is one of 8 in phase 1, and was the 46th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

3 of the 51 studies testing levodopa in Parkinson Disease are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About levodopa

Levodopa: first FDA approval 1970 (LARODOPA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing levodopa in Parkinson Disease, or all of them as a file.
02

Study summary

The Phase 1 PK study is planned to evaluate the food effect on WD-1603 pharmacokinetics

03

Conditions studied

  • Parkinson Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Normal, healthy adult human volunteers between 18 to 45 years of age (both inclusive).
  2. Having a (BMI) between 18.5 to 29.9 (both inclusive), calculated as weight in kg / height in m2.
  3. Not having any significant disease or abnormal findings during screening, medical history, clinical examination, laboratory evaluations, 12- lead and X-ray chest (P/A view) recordings.
  4. Able to understand and comply with the study procedures, in the opinion of the principal investigator.
  5. Able to give voluntary written for participation in the trial.
  6. In case of female subjects:

a. Surgically sterilized at least 6 months prior to study participation or If of child bearing potential is willing to use a suitable and effective double barrier method or intra uterine device during the study.

And b. Serum Pregnancy test must be negative.

Exclusion criteria

Exclusion Criteria:

  1. Known or idiosyncratic reaction to Carbidopa or Levodopa or any of the or any related drug.
  2. History or presence of any disease or condition which might compromise the haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular, immunological, dermatological, gastrointestinal or any other body system.
  3. Ingestion of a medicine (prescribed \& over the counter (OTC) medication including herbal remedies) at any time within 14 days before dosing in Period I. In any such case subject selection will be at the discretion of the Principal Investigator.
  4. Any history or presence of asthma (including aspirin induced asthma) or nasal polyp or NSAIDs induced urticaria.
  5. Use of any recreational drugs or history of drug addiction or testing positive in pre-study drug scans.
  6. A recent history of harmful use of alcohol (less than 2 years), i.e. alcohol consumption of more than 14 standard drinks per week for men and more than 7 standard drinks per week for women (A standard drink is defined as 360 ml of beer or 150 ml of wine or 45 ml of 40% distilled spirits, such as rum, whisky, brandy etc) or consumption of alcohol or alcoholic products within 48 hours prior to dosing in Period I.
  7. Smokers, who smoke 10 or more than 10 cigarettes / day or inability to abstain from smoking during the study.
  8. The presence of abnormal laboratory values during screening.
  9. History or presence of psychiatric disorders.
  10. A history of difficulty in donating blood.
  11. Donation of blood (1 unit or 350 mL) within a period of 90 days prior to the first dose of study medication.
  12. Receipt of an medicinal product or participation in a drug research study within a period of 90 days prior to the first dose of study medication**.

    ** If investigational medicinal product is received within 90 days where there is no blood loss except safety lab testing, subject can be included considering 10 half-lives duration of investigational medicinal product received.

  13. A positive hepatitis screen including surface antigen and/or antibodies.
  14. A positive test result for (1 \&/or 2) antibody.
  15. An unusual diet, for whatever reason (e.g. low-sodium), for four weeks prior to receiving the study medicine in period I. In any such case subject selection will be at the discretion of the Principal Investigator.
  16. Consumption of grapefruit or grapefruit products within 72 hours prior to dosing in period-I.
  17. Difficulty in swallowing oral solid dosage form like tablets or capsules.
  18. Nursing mothers (females).
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
8 participants (estimated)

Study arms

  • Experimental
    Treatment A

    Treatment A will be given under fed conditions by intra-oral single dose administration

    Drug: WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS

  • Experimental
    Treatment B

    Treatment B will be given intra-orally and orally under fed conditions by single dose administration

    Drug: WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS

  • Experimental
    Treatment C

    Treatment C will be given orally under fed conditions by single dose administration

    Drug: WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS

  • Experimental
    Treatment D

    Treatment D will be given orally under fasting conditions by single dose administration

    Drug: WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax

    Pharmacokinetics Measurements to Determine Cmax for Carbidopa (CD) and Levodopa (LD) Plasma Concentrations

    Time frame: Day 1 and Day 2

  2. AUC0-t

    Pharmacokinetics Measurements to Determine AUC0-t for Carbidopa (CD) and Levodopa (LD) Plasma Concentrations

    Time frame: Day 1 and Day 2

  3. AUC0-∞

    Pharmacokinetics Measurements to Determine AUC0-∞ for Carbidopa (CD) and Levodopa (LD) Plasma Concentrations

    Time frame: Day 1 and Day 2

Secondary outcomes

  1. Tmax

    Pharmacokinetics Measurements to Determine Tmax for Carbidopa (CD) and

    Time frame: Day 1 and Day 2

  2. t1/2

    Pharmacokinetics Measurements to Determine t1/2 for Carbidopa (CD) and

    Time frame: Day 1 and Day 2

07

Study locations

1 of 1 sites recruiting
  • Lambda Therapeutic Research Ltd.
    Ahmedabad, India
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2020 (actual). Primary completion is estimated for Sep 2020, 0 months after the start.

Of 127 industry-sponsored phase 1 interventional studies under Parkinson Disease, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 24. This study's planned 0 months is below that.

Counting every sponsor, half of 204 studies reached it within 18 months; a quarter within 5 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2020
First posted
Aug 14, 2020
StartActual
Aug 13, 2020
Primary completionEst.
Sep 5, 2020
CompletionEst.
Feb 13, 2021
Last update
Sep 10, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04513340
Lead sponsor
Hong Kong WD Pharmaceutical Co., Limited
Responsible party
Sponsor
First posted
Aug 14, 2020
Start date
Aug 13, 2020
Primary completion
Sep 5, 2020 (estimated)
Completion
Feb 13, 2021 (estimated)
Last update
Sep 10, 2020

Study contacts

Xiaoxiong Wei, Doctor
Contact
xiaoxiong.wei@wdpharma.com
+86-21-6859-9718

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: WD-1603 · Levodopa

Start the discussion